Hepatomegaly in Type 1 Diabetes Mellitus: When to Suspect of Glycogenic Hepatopathy?

Joana Jardim\textsuperscript{a,c}, Eunice Trindade\textsuperscript{a}, Fatima Carneiro\textsuperscript{b}, Jorge Amil Dias\textsuperscript{a}

Abstract

Uncontrolled type 1 diabetes mellitus is associated with recognized short- and long-term complications. The authors describe a case of a female adolescent, with history of poorly controlled type 1 diabetes mellitus, who presented with tender hepatomegaly and elevated liver enzymes. Her growth and pubertal development were appropriated for age. After excluding infectious and autoimmune causes of liver disease, a liver biopsy was performed and histology revealed glycogenosis. Glycogenic hepatopathy is characterized by abnormal glycogen accumulation in hepatocytes. It is a reversible condition, with good glycemic control, and is not known to progress to fibrosis. This entity should be distinct from other causes of hepatomegaly and elevated liver enzymes, in diabetic patients, such as nonalcoholic fatty liver disease. Although glycogenic hepatopathy is a major cause of hepatomegaly in type 1 diabetes mellitus, it is rare and likely under-recognized, the diagnosis has implications in the management and outcome.

Keywords: Glycogenic hepatopathy; Diabetes mellitus; Hepatomegaly

Introduction

In the clinical setting of diabetes, hepatomegaly can be caused by hepatic glycogenosis or nonalcoholic fatty liver disease (NAFLD) \cite{1}. Glycogenic hepatopathy (GH) is a rare and under-recognized condition associated with poorly controlled type 1 diabetes mellitus (T1DM) in children, adolescents and young adults, while NAFLD is more frequent in older and obese patients with type 2 diabetes \cite{1, 2}. GH consists in glycogen accumulation in the hepatocytes, resulting in hepatomegaly and elevated liver enzymes \cite{2-6}. The clinical course is benign and GH is reversible if glycemia is controlled \cite{1-9}.

Case Report

A 14-year-old female was referred to the pediatric gastroenterology outpatient clinic due to chronic abdominal pain and intermittent hepatomegaly. She had T1DM diagnosed since 11 years of age, under insulin therapy, but with poor glycemic control, hemoglobin A\textsubscript{1C} 13%.

There was no history of liver disease, blood transfusion, exposure to toxins, medication and radiation or cholelithiasis.

She was frequently nauseated and had abdominal pain referred to the right upper quadrant. The patient denied history of jaundice, pruritis, weight loss, hematemesis or rectal bleeding. Past medical history did not reveal additional relevant information.

On physical examination she had tender hepatomegaly, extending 2 cm below the right costal margin. Her weight was on the 25th-50th centile and 10th-25th for height. Pu-
glycemic control was achieved, later on. After biopsy, clinical improvement was only seen when secondary to poorly controlled diabetic disease was suggestive of GH. Histological examination results of chronic hyperinsulinemia and hepatocellular injury are analyzed. It is important that pediatricians be aware of GH and the association with poorly controlled T1DM, as insulin-resistant hepatic glycogen accumulation is the most common cause of hepatomegaly and abnormal liver biochemistry, in children and young adults with insulin-dependent diabetes mellitus.

**Discussion**

GH results from the accumulation of excessive glycogen in the hepatocytes [1-9]. Typically, it is associated with uncontrolled T1DM, although it has been recently reported in type 2 [6, 8]. GH presents with abdominal pain, nausea, vomiting, hepatomegaly and elevated liver enzymes [2-6]. Glycogen loading of the liver was first described as a component of Mauriac syndrome: growth retardation, hepatomegaly, cushingoid features and delayed puberty [1, 2, 5, 8, 9]. However, it is now known that GH can develop without the full spectrum of the features of Mauriac syndrome [1, 5, 8, 9].

In the clinical setting of diabetes, it is important to distinguish GH from NAFLD, in patients with abnormal liver tests. Persistent mild alterations in liver enzymes are more in favor of NAFLD, whereas aminotransferase flares are more suggestive of GH [8]. Contrary to NAFLD, GH is not known to progress to fibrosis and the hepatic changes are reversible with adequate glycemic control [2, 3, 6, 8].

The wide fluctuation in glucose and insulin levels is an essential element in the pathophysiology of GH. High levels of glucose cause an insulin independent inflow of glucose into the hepatocytes where it is rapidly phosphorilated and trapped in the cell. Subsequent treatment of high glucose levels with insulin causes the trapped glucose to polymerize to glycogen. Glycogen production persists for some time after insulin levels are declined [8]. In NAFLD lipid accumulation results of chronic hyperinsulinemia and hepatocellular insulin resistance [10].

On liver biopsy, GH displays a characteristic vegetal-like appearance of the hepatocytes, with no evidence of fibrosis, necrosis or inflammation [3-5, 7]. The need for liver biopsy, in this context, is a debated issue. Some authors favor the need of liver biopsy to make the distinction between GH and NAFLD, to obtain information for the prediction of prognosis, as pathobiology and therapy are different [1, 2, 6, 8]. The other hand, some recent publications suggest that, although NAFLD cannot be excluded by history, physical examination or ultrasound, invasive evaluations should be postponed until the response of metabolic control is accomplished [1, 2]. In our case, liver biopsy was performed in order to differentiate the pathological findings, as glycemic control was very difficult to achieve, while the patient persistently maintained symptomatic hepatomegaly and abnormal liver biochemistry.

It is important that pediatricians be aware of GH and the association with poorly controlled T1DM, as insulin-resistant hepatic glycogen accumulation is the most common cause of hepatomegaly and abnormal liver biochemistry, in children and young adults with insulin-dependent diabetes mellitus.

**Grant Support**

The authors declare that there was no financial support, including governmental assistance and pharmaceutical com-
pany support, involved in this research.

**Conflict of Interest**

The authors declare that there is no conflict of interest.

**References**